Comparison Overview

Astellas Pharma

VS

Grifols

Astellas Pharma

2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo, JP, 103-8411
Last Update: 2026-01-18
Between 750 and 799

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 12,110
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Grifols

Parc Empresarial Can Sant Joan, Sant Cugat del Vallès, 08174, ES
Last Update: 2026-01-18
Between 750 and 799

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 13,839
Subsidiaries: 4
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Astellas Pharma
100%
Compliance Rate
0/4 Standards Verified
Grifols
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Grifols in 2026.

Incident History — Astellas Pharma (X = Date, Y = Severity)

Astellas Pharma cyber incidents detection timeline including parent company and subsidiaries

Incident History — Grifols (X = Date, Y = Severity)

Grifols cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/astellaspharmainc.jpeg
Astellas Pharma
Incidents

No Incident

https://images.rankiteo.com/companyimages/grifols.jpeg
Grifols
Incidents

No Incident

FAQ

Astellas Pharma company demonstrates a stronger AI Cybersecurity Score compared to Grifols company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Grifols company has disclosed a higher number of cyber incidents compared to Astellas Pharma company.

In the current year, Grifols company and Astellas Pharma company have not reported any cyber incidents.

Neither Grifols company nor Astellas Pharma company has reported experiencing a ransomware attack publicly.

Neither Grifols company nor Astellas Pharma company has reported experiencing a data breach publicly.

Neither Grifols company nor Astellas Pharma company has reported experiencing targeted cyberattacks publicly.

Neither Astellas Pharma company nor Grifols company has reported experiencing or disclosing vulnerabilities publicly.

Neither Astellas Pharma nor Grifols holds any compliance certifications.

Neither company holds any compliance certifications.

Grifols company has more subsidiaries worldwide compared to Astellas Pharma company.

Grifols company employs more people globally than Astellas Pharma company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Astellas Pharma nor Grifols holds SOC 2 Type 1 certification.

Neither Astellas Pharma nor Grifols holds SOC 2 Type 2 certification.

Neither Astellas Pharma nor Grifols holds ISO 27001 certification.

Neither Astellas Pharma nor Grifols holds PCI DSS certification.

Neither Astellas Pharma nor Grifols holds HIPAA certification.

Neither Astellas Pharma nor Grifols holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Typemill is a flat-file, Markdown-based CMS designed for informational documentation websites. A reflected Cross-Site Scripting (XSS) exists in the login error view template `login.twig` of versions 2.19.1 and below. The `username` value can be echoed back without proper contextual encoding when authentication fails. An attacker can execute script in the login page context. This issue has been fixed in version 2.19.2.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N
Description

A DOM-based Cross-Site Scripting (XSS) vulnerability exists in the DomainCheckerApp class within domain/script.js of Sourcecodester Domain Availability Checker v1.0. The vulnerability occurs because the application improperly handles user-supplied data in the createResultElement method by using the unsafe innerHTML property to render domain search results.

Description

A Remote Code Execution (RCE) vulnerability exists in Sourcecodester Modern Image Gallery App v1.0 within the gallery/upload.php component. The application fails to properly validate uploaded file contents. Additionally, the application preserves the user-supplied file extension during the save process. This allows an unauthenticated attacker to upload arbitrary PHP code by spoofing the MIME type as an image, leading to full system compromise.

Description

A UNIX symbolic link following issue in the jailer component in Firecracker version v1.13.1 and earlier and 1.14.0 on Linux may allow a local host user with write access to the pre-created jailer directories to overwrite arbitrary host files via a symlink attack during the initialization copy at jailer startup, if the jailer is executed with root privileges. To mitigate this issue, users should upgrade to version v1.13.2 or 1.14.1 or above.

Risk Information
cvss3
Base: 6.0
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:H
cvss4
Base: 6.0
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

An information disclosure vulnerability exists in the /srvs/membersrv/getCashiers endpoint of the Aptsys gemscms backend platform thru 2025-05-28. This unauthenticated endpoint returns a list of cashier accounts, including names, email addresses, usernames, and passwords hashed using MD5. As MD5 is a broken cryptographic function, the hashes can be easily reversed using public tools, exposing user credentials in plaintext. This allows remote attackers to perform unauthorized logins and potentially gain access to sensitive POS operations or backend functions.